Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascletis Reports Initial Success in PD-L1 Trial for Chronic Hepatitis B

publication date: May 5, 2021

Ascletis Pharma of Hangzhou reported positive Phase IIa trial results from its in-licensed PD-L1 in patients with chronic hepatitis B. ASC22 (envafolimab) is a first-in-class, subcutaneously administered PD-L1 antibody. The Phase IIa trial administered a single dose at three levels to three patients at each level. Eight of the nine patients responded, and one patient in the high-dose cohort had a maximum reduction in HBsAg, the efficacy endpoint. In 2019, Ascletis in-licensed China rights to ASC22 from Suzhou Alphamab for viral indications. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital